Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714049 · ClinicalTrials.gov registry record · Phase 4
Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy
A Phase 4 study, sponsored by San Diego Sexual Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT02714049: Clinical Trial Phase 4 study, sponsored by San Diego Sexual Medicine.
NCT02714049 is a Phase 4 study that was terminated before completion, run by San Diego Sexual Medicine. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02714049, a Phase 4 study, was terminated before completion, sponsored by San Diego Sexual Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
Unblinded study of flibanserin for 8 weeks with responders randomized 1:1 to receive study medication alone vs. study medication and sex therapy for 12 additional weeks.
Primary Outcome
The primary objective of this study is to determine whether efficacy of flibanserin as determined by changes in the desire domain of the Female Sexual Function Index (FSFI) in women who respond to the study medication is greater when sex therapy is performed concomitant with the use of the medication.
Interventions
- DRUG flibanserin
- BEHAVIORAL sex therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-01-25 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 4 |
Why NCT02714049 stopped before completion
NCT02714049 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which flibanserin is the first listed.
NCT02714049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02714049 about?
NCT02714049 is a clinical study titled "Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy". Unblinded study of flibanserin for 8 weeks with responders randomized 1:1 to receive study medication alone vs. study medication and sex therapy for 12 additional weeks.
What is the current status of trial NCT02714049?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2017-01-25. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT02714049?
The interventions under investigation include: flibanserin (DRUG), sex therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02714049?
This trial is sponsored by San Diego Sexual Medicine, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02714049's enrollment target sits among peer trials
23 1725th of 2000 higher than 270 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI